Adipotide 5mg

Adipotide specifically targets and kills blood vessels supplying white fat tissue.

Adipotide, or Prohibitin-Targeting Peptide 1 (Prohibitin-TP01), is an anti-obesity peptide which specifically targets and kills blood vessels supplying white fat tissue. Data demonstrating substantial weight loss, reduction in body mass index and abdominal circumference, and marked improvements in insulin resistance in obese rhesus monkeys was published in the peer-reviewed journal Science Translational Medicine in November 2011.

To determine whether Adipotide FTPP might kill fat cells, it was produced and evaluated using research studies in 2011. According to investigations conducted on primates, Adipotide seemed to target apoptosis in rhesus monkeys’ white adipose tissue (fat) blood vessels. Fat cells were suggested by researchers to simply perish following a deprivation of blood supply. Rapid weight loss, quick reduction in body mass index (BMI), and reduced insulin resistance features were the overall hypothesized outcomes of this particular intervention. Interestingly, Adipotide and subsequent fat reduction were speculated to have improved weight and contributed to changes in the observed eating habits of the primates.

There is a possibility that a protein receptor known as prohibitin may be responsible for mediating the targeting of Adipotide to the blood arteries that supply fat cells. Prohibitin is a membrane protein found in cancer cells and blood arteries serving white fat. Perhaps it is only present in these two places. These findings have indicated that this protein may be associated with adiposity.

This product is provided purely for research purposes only and not for human use.

[i] K.F. Barnhart et al., “A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys,” Sci. Transl. Med., vol. 3, no. 108, p. 108ra112, Nov. 2011.

[ii] M. G. Kolonin, P. K. Saha, L. Chan, R. Pasqualini, and W. Arap, “Reversal of obesity by targeted ablation of adipose tissue,” Nat. Med., vol. 10, no. 6, pp. 625–632, Jun. 2004.

[iii] F.I. Staquicini et al., “Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients,” Proc. Natl. Acad. Sci. U. S. A., vol. 108, no. 46, pp. 18637–18642, Nov. 2011.

[iv] D.-H. Kim et al., “Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium,” Diabetes, vol. 61, no. 9, pp. 2299–2310, Sep. 2012.

[v] L. Criscione, “Comment on ‘a peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys,’” Sci. Transl. Med., vol. 4, no. 131, pp. 131le2; author reply 131lr2, Apr. 2012.

In compliance with the law, we cannot offer guidance on how to consume this compound or its intended use. Our product is being sold purely as a chemical compound, not as a medicine, food, or therapeutic product.

We do not dictate the manner in which you utilize this product.

Legally we don’t provide directions on how this compound is taken nor what it should or should not be used for, we are selling this chemical compound solely as a chemical compound and not as a medicine, food, therapeutic good.

We will not tell you what to do with it.